Skip to main content

Science and Partners

Impact of Alzheimer’s disease and other cognitive disorders in Canada


Population aging and growing incidence of cognitive disorders

An estimated 713,000 Canadians were living with dementia in 2022, of which Alzheimer’s disease (AD) is the most common type.

Canada’s population is aging rapidly. Approximately 76,000 new cases of dementia are diagnosed every year.

The number of cases of dementia is expected to rise to 937,000 by 2031, an increase of 31%.


Impact on our healthcare system

Dementia is a major economic burden on the Canadian healthcare system. In fact, the direct annual costs of dementia in Canada are estimated to almost 13 billion dollars in 2022.


Healthy lifestyle habits as a preventive measure

There is currently no cure for Alzheimer’s disease and related diseases.

Despite that fact, science shows that up to 40% of AD cases could be attributable to modifiable risk factors.

The message is clear: approaches focused on adopting and maintaining healthy lifestyle habits represent a potentially effective way for preventing or delaying cognitive decline and dementia.

The Luci app was designed to harness this powerful preventive approach. Building on proven behavioural change theories, our team of healthy lifestyle advisors supports participants who want to adopt healthy lifestyle habits in three areas: healthy eating, physical activity, and intellectual stimulation.

Scientific committee

One of Luci's prime objectives is to advance scientific knowledge in the area of cognitive decline prevention.

Luci’s scientific validation process was established jointly with a scientific committee comprised of six renowned researchers:

Sylvie Belleville

Sylvie Belleville, PhD

Michel Boivin

Michel Boivin, MD

Guy Paré

Guy Paré, PhD

Simon Bacon

Simon L. Bacon, PhD, FTOS, FCCS, FABMR

Kim Lavoie

Kim Lavoie, PhD, FCPA, FABMR

Guylaine Ferland

Guylaine Ferland, PhD

Scientific studies

The Luci program is undergoing a clinical validation process in three phases: proof of concept, feasibility study and efficacity study.

Are you between the ages of 50 and 70? Add your name to our volunteer list if you wish to participate to our next study.


Scientific Publications

  • Lussier, I., Guillemont, J., Bacon, S.L., Boivin, M., Ferland, G., Lavoie, K., Paré, G. and Belleville, S. (2021), Multidomain interventions for dementia risk reduction: Can we detect a change in the signal?. Alzheimer’s Dement., 17: e053914.

Our partners